Argenx, a Dutch developer of antibodies that treat cancer and severe autoimmune diseases, has filed for a U.S. IPO. The stock will trade on the NASDAQ under the ticker symbol “ARGX”. Argenx’s backers include Aquila Capital, Forbion Capital Partners, OrbiMed, MPM Capital and Seventure Partners.